Short-course beta-lactam prophylaxis reduces early-onset VAP in mechanically ventilated patients with acute brain injury.
Photo by Ava Sol / Unsplash
Key Takeaway
Consider short-course beta-lactam prophylaxis for early-onset VAP prevention in high-risk mechanically ventilated ABI patients, noting mixed evidence and guideline caution.
This systematic review and meta-analysis assessed the efficacy of short-course systemic beta-lactam antibiotic prophylaxis compared with control in mechanically ventilated patients with acute brain injury (ABI). The analysis included 1,673 patients across ICU settings. The primary outcomes examined were early-onset VAP (≤ 96 hours), late-onset VAP (> 96 hours), overall VAP, and ICU mortality. Secondary outcomes included mechanical ventilation duration, ICU and hospital length of stay (LOS), and time to first VAP.
The meta-analysis demonstrated a reduction in overall VAP, with a risk ratio (RR) of 0.65 (95% CI: 0.48-0.90, P < 0.001). Specifically, early-onset VAP was significantly reduced, showing an RR of 0.41 (95% CI: 0.33-0.52, P < 0.001), based on 88 cases in 754 patients receiving prophylaxis versus 240 cases in 832 control patients. Conversely, late-onset VAP showed no effect (RR = 1.13, 95% CI: 0.72-1.78, P = 0.07). ICU mortality was unaffected (RR = 0.91, 95% CI: 0.76-1.08, P = 0.27).
Regarding secondary outcomes, prophylaxis was associated with a reduction in ICU LOS (mean difference [MD] = -2.05 days, 95% CI: -3.73 to -0.37, P = 0.01) and hospital LOS (MD = -5.02 days, 95% CI: -9.20 to -0.85, P = 0.02). No significant difference was found in ventilation duration (MD = -1.36 days, 95% CI: -2.91 to 0.19, P = 0.09) or time to first VAP (MD = 1.04 days, 95% CI: -0.87 to 2.95, P = 0.29). Safety data, adverse events, and tolerability were not reported. Key limitations include heterogeneity, potential selection bias, and low-to-moderate bias in randomized controlled trials. The evidence supports targeted use in high-risk cases, such as those with a Glasgow Coma Scale score < 8, while acknowledging that efficacy in ABI remains debated and guidelines do not endorse universal prophylaxis.
More on Acute brain injury
High-altitude ICU study finds 21% AKI incidence in neurocritical patients
High-altitude ICU patients face kidney injury risk
This retrospective cohort study of 390 adult neurocritical patients at a high-altitude ICU found that 83 patients (21.3%) developed acute ki…
A study of 390 adults in a high-altitude ICU found that 1 in 5 developed acute kidney injury, linked to older age and higher hemoglobin leve…
Meta-analysis of antimicrobial resistance prevalence in Tanzanian hospital pathogens
Common Antibiotics Are Failing in Tanzania, New Data Reveals
This systematic review and meta-analysis synthesizes data from 28 studies on antimicrobial resistance in clinically relevant pathogens withi…
This research shows that common antibiotics are losing their power in Tanzania, urging a critical update to how infections are treated.
Pharmacist-led stewardship improved antibiotic appropriateness and outcomes in adult HAP or VAP patients.
Can a pharmacist-led program make antibiotic use safer and more effective for pneumonia patients?
This randomized controlled trial evaluated a pharmacist-led antimicrobial stewardship program in 699 adult patients with hospital-acquired o…
A pharmacist-led program significantly improved antibiotic prescriptions and reduced unnecessary drug exposure for pneumonia patients in a h…
Meta-analysis finds no significant difference in outcomes between high- and low-dose ceftriaxone for non-CNS infections
Do higher doses of a common antibiotic help adults with infections?
A meta-analysis of eight studies involving 5145 adults with non-CNS infections found no statistically significant difference in clinical cur…
Higher doses of the antibiotic ceftriaxone show no clear benefit over the standard 1-gram daily dose for curing infections in adults, based …
View Original Abstract ↓
BACKGROUND: Ventilator-associated pneumonia (VAP) affects 30-50% of mechanically ventilated patients with acute brain injury (ABI), exceeding general ICU rates (10-20%) due to aspiration risks and immunosuppression, prolonging ICU stays and morbidity. Although short-course antibiotic prophylaxis (AP; e.g., ceftriaxone) targets early VAP, efficacy in ABI remains debated amid mixed evidence, resistance concerns, and non-endorsement by IDSA/ATS guidelines.
METHODS: We searched PubMed, Cochrane Library, and Web of Science (inception to October 2024) for RCTs and non-RCTs on systemic AP (short-course beta-lactams) for VAP prevention in ABI (TBI, SAH, stroke, post-arrest coma) requiring ventilation ≥ 48 h.
PRIMARY OUTCOMES: early-onset VAP (≤ 96 h), late-onset VAP (> 96 h), overall VAP, ICU mortality. Secondaries: mechanical ventilation duration, ICU/hospital length of stay (LOS), time to first VAP. Random-effects meta-analysis; heterogeneity via I; risk of bias (RoB 2.0/ROBINS-I).
RESULTS: Ten studies (5 RCTs [n = 586], 5 non-RCTs [n = 1,087]; total n = 1,673) were included. AP reduced overall VAP (RR = 0.65, 95% CI: 0.48-0.90, P < 0.001; I = 75.9%) and early-onset VAP (RR = 0.41, 95% CI: 0.33-0.52, P < 0.001; I = 0%; events: 88/754 AP vs. 240/832 control). No effect on late-onset VAP (RR = 1.13, 95% CI: 0.72-1.78, P = 0.07; I = 64.8%) or ICU mortality (RR = 0.91, 95% CI: 0.76-1.08, P = 0.27; I = 0%). Secondaries: Reduced ICU LOS (MD = - 2.05 days, 95% CI: - 3.73 to - 0.37, P = 0.01; I = 46%) and hospital LOS (MD = - 5.02 days, 95% CI: - 9.20 to - 0.85, P = 0.02; I = 70.8%); no difference in ventilation duration (MD = - 1.36 days, 95% CI: - 2.91 to 0.19, P = 0.09) or time to VAP (MD = 1.04 days, 95% CI: - 0.87 to 2.95, P = 0.29). RCTs showed low-moderate bias; non-RCTs moderate-serious (confounding).
CONCLUSION: Short-course AP reduces early/overall VAP and LOS in ABI without impacting late VAP or mortality, supporting targeted use in high-risk cases (e.g., GCS < 8) per stewardship principles. However, heterogeneity, resistance gaps, and guideline caution warrant larger RCTs with non-ABI comparatives to mitigate selection bias and confirm specificity.
Metformin, fluvoxamine, or ivermectin for non-hospitalized COVID-19 adults in a Phase 3 trial
Metformin Cuts Long Covid Risk by 40%
Related in Infectious Disease
Systematic review and meta-analysis shows cefotiam reduces postoperative infection in clean surgery
Cefotiam cuts post-surgery infection risk by half compared to no antibiotics
This systematic review and meta-analysis evaluated cefotiam prophylaxis versus no antibiotic prophylaxis or other beta-lactam agents in adul…
A large review found cefotiam lowers infection risk after clean surgery. It works as well as other common antibiotics without causing more s…
Review of Fluoroquinolone Restriction Implementation Modifications for C. difficile Prevention
Hospital plans to stop risky drugs often changed during real-world rollout
This review analyzes modifications to fluoroquinolone restriction implementation strategies from the FIRST trial across four diverse hospita…
Plans to limit risky fluoroquinolones often changed during rollout. Rural hospitals needed more tweaks than academic centers.
Systematic review and meta-analysis finds bacterial co-infection in 17.3% of hospitalized influenza patients
Hospital data shows high rates of bacterial co-infection in influenza patients
This systematic review and meta-analysis of 111,889 hospital-attended patients with laboratory-confirmed influenza found a pooled prevalence…
Analysis of over 111,000 patients reveals that bacterial co-infection occurs in 17.3% of hospital cases with confirmed influenza infection.
Systematic review examines tumor microenvironment mechanisms in lung cancer brain metastases
New brain strategies target lung cancer before it spreads
This systematic review explores the complex mechanisms driving brain metastasis in patients with lung cancer. The authors synthesize how int…
Doctors are finding clever new ways to fight lung cancer that has spread to the brain without breaking the body's natural barriers
From Other Specialties
Therapeutic Touch Reduces Crying and Improves Sleep in Infants With Colic
Therapeutic touch reduces crying in babies with colic
This randomized controlled trial in 96 infants with colic found that therapeutic touch based on Watson's Human Care Theory significantly red…
A new trial shows gentle therapeutic touch helps babies cry less and sleep better when they have infantile colic.
Mycophenolate mofetil non-inferior to prednisone for first-episode nephrotic syndrome in children
Mycophenolate Mofetil Offers Alternative to Steroids for Nephrotic Syndrome
This phase 3 non-inferiority trial randomized 272 children aged 1-10 years with first-episode steroid-sensitive nephrotic syndrome to mycoph…
A new trial shows mycophenolate mofetil works as well as prednisone for children with nephrotic syndrome, with fewer steroid side effects.
AquOTic water competency intervention improves outcomes in children with autism
Water therapy improves skills for children with autism spectrum disorder
This pre-post cohort study of 37 children with autism ages 5 to 9 found that a 10-week occupational therapy-based water competency intervent…
A water-based occupational therapy program significantly improved performance and satisfaction scores in children with autism spectrum disor…
Play-based cognitive flexibility training boosts creativity in third graders
Playful workshops boost story skills and flexible thinking for third graders
This RCT in 249 third graders found that a 14-session play-based workshop significantly improved narrative creativity and cognitive flexibil…
A fun 14-session workshop helped third graders write better stories and think more flexibly than peers in regular classes.